KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.

Ciao-Sin Chen, Gary Zirpoli, William E Barlow, G Thomas Budd, Bryan McKiver, Lajos Pusztai, Gabriel N Hortobagyi, Kathy S Albain, M Imad Damaj, Andrew K Godwin, Alastair Thompson, N Lynn Henry, Christine B Ambrosone, Kathleen A Stringer, Daniel L Hertz

J Natl Compr Canc Netw 21(11) 1172-1180.e3

PMID37935109
PMCIDPMC10976748
DOI10.6004/jnccn.2023.7062
发表日期2023-11-07
入排依据:This is a secondary analysis of a Phase III trial focusing on a predictive biomarker (vitamin D) for a toxicity endpoint (chemotherapy-induced peripheral neuropathy), not on a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the inclusion criteria.
摘要

摘要

BACKGROUND: Prior work suggests that patients with vitamin D insufficiency may have a higher risk of chemotherapy-induced peripheral neuropathy (CIPN) from paclitaxel. The objective of this study was to validate vitamin D insufficiency as a CIPN risk factor. METHODS: We used data and samples from the prospective phase III SWOG S0221 (ClinicalTrials.gov identifier: NCT00070564) trial that compared paclitaxel-containing chemotherapy regimens for early-stage breast cancer. We quantified pretreatment 25-hydroxy-vitamin D in banked serum samples using a liquid chromatography-tandem mass spectrometry targeted assay. We tested the association between vitamin D insufficiency (≤20 ng/mL) and grade ≥3 sensory CIPN via multiple logistic regression and then adjusted for self-reported race, age, body mass index, and paclitaxel schedule (randomization to weekly or every-2-week dosing). We also tested the direct effect of vitamin D deficiency on mechanical hypersensitivity in mice randomized to a regular or vitamin D-deficient diet. RESULTS: Of the 1,191 female patients in the analysis, 397 (33.3%) had pretreatment vitamin D insufficiency, and 195 (16.4%) developed grade ≥3 CIPN. Patients with vitamin D insufficiency had a higher incidence of grade ≥3 CIPN than those who had sufficient vitamin D (20.7% vs 14.2%; odds ratio [OR], 1.57; 95% CI, 1.14-2.15; P=.005). The association retained significance after adjusting for age and paclitaxel schedule (adjusted OR, 1.65; 95% CI, 1.18-2.30; P=.003) but not race (adjusted OR, 1.39; 95% CI, 0.98-1.97; P=.066). In the mouse experiments, the vitamin D-deficient diet caused mechanical hypersensitivity and sensitized mice to paclitaxel (both P<.05). CONCLUSIONS: Pretreatment vitamin D insufficiency is the first validated potentially modifiable predictive biomarker of CIPN from paclitaxel. Prospective trials are needed to determine whether vitamin D supplementation prevents CIPN and improves treatment outcomes in patients with breast and other cancer types.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。